Once a person reaches menopause , they can often experience a wide array of life-disrupting symptoms, such as hot flashes , disrupted sleep , vaginal dryness , or mood swings . These are due to fluctuating or dropping hormone levels, particularly estrogen .
The main way of managing menopause symptoms is through hormone replacement therapy (HRT) , also known as menopause hormone therapy. Historically, doctors had been concerned that hormone therapy could sometimes result in serious side effects but the narrative is now shifting, as mounting evidence increasingly suggests not only that HRT is safe but that it may be associated with more benefits than previously thought.
Some research had suggested that HRT use was linked to heightened dementia risk but newer evidence drawing on global data has systematically contradicted that suggestion. Most recently, a large review published in The Lancet Healthy Longevity in December 2025, concluded that hormone therapy for menopause did not increase dementia risk .
It notes a historical concern about serious adverse effects and contrasts it with contemporary evidence suggesting safety and potential broader benefits.
A specific large review, The Lancet Healthy Longevity (December 2025), is cited as not finding an increased risk of dementia with HRT, drawing on data from 10 studies (nine observational, one randomized controlled trial) totaling over 1 million participants.
This body of work is presented as contributing to a regulatory shift, including the FDA’s November 2025 decision to remove black box warnings for HRT products.
It explicitly notes that the Lancet Obstetrics, Gynaecology, & Women’s Health study (January 2026) suggests a potential role for HRT in weight maintenance after menopause, based on interactions with GLP-1 receptor agonist therapy (specifically tirzepatide, branded as Zepbound) used for weight loss.
However, the authors emphasize the observational nature of this study and caution against inferring causality.
They call for prospective trials to determine whether menopausal hormone therapy modifies response to obesity pharmacotherapy.
The conclusion stated is that HRT did not increase dementia risk, aligning with regulatory actions in late 2025 aimed at clarifying safety signals.
The reported outcome was a statistically greater weight loss magnitude in the HRT-plus-tirzepatide group, quantified as a 35% greater loss relative to tirzepatide alone.
Observational design is highlighted as a limitation.
The authors advocate prospective trials to clarify whether menopausal hormone therapy modifies response to GLP-1 pathway–targeted obesity treatments.
Specific adverse events, risk magnitudes, or comparative safety data beyond the dementia signal and regulatory action are not detailed in the source.
The need for prospective trials to verify whether menopausal status and HRT use modify pharmacologic obesity treatment response is explicitly stated.